Symphogen A/S - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Symphogen A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Symphogen A/S - Product Pipeline Review - 2014', provides an overview of the Symphogen A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Symphogen A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Symphogen A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Symphogen A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Symphogen A/S's pipeline products

Reasons to buy

- Evaluate Symphogen A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Symphogen A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Symphogen A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Symphogen A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Symphogen A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Symphogen A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Symphogen A/S Snapshot 5
Symphogen A/S Overview 5
Key Information 5
Key Facts 5
Symphogen A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Symphogen A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Symphogen A/S - Pipeline Products Glance 13
Symphogen A/S - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Symphogen A/S - Drug Profiles 15
Sym-002 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Sym-003 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Sym-005 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Sym-006 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Sym-011 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Sym-013 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibodies 1 for Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibodies for Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibodies to Target Multiple Receptors for Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Sym-007 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Sym-008 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sym-009 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Sym-012 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Sym-014 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SYM-015 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Symphogen A/S - Pipeline Analysis 30
Symphogen A/S - Pipeline Products by Target 30
Symphogen A/S - Pipeline Products by Molecule Type 31
Symphogen A/S - Pipeline Products by Mechanism of Action 32
Symphogen A/S - Recent Pipeline Updates 33
Symphogen A/S - Dormant Projects 34
Symphogen A/S - Discontinued Pipeline Products 35
Discontinued Pipeline Product Profiles 35
rozrolimupab 35
Symphogen A/S - Company Statement 36
Symphogen A/S - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Symphogen A/S, Key Information 5
Symphogen A/S, Key Facts 5
Symphogen A/S - Pipeline by Indication, 2014 8
Symphogen A/S - Pipeline by Stage of Development, 2014 9
Symphogen A/S - Monotherapy Products in Pipeline, 2014 10
Symphogen A/S - Out-Licensed Products in Pipeline, 2014 11
Symphogen A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Symphogen A/S - Preclinical, 2014 13
Symphogen A/S - Discovery, 2014 14
Symphogen A/S - Pipeline by Target, 2014 30
Symphogen A/S - Pipeline by Molecule Type, 2014 31
Symphogen A/S - Pipeline Products by Mechanism of Action, 2014 32
Symphogen A/S - Recent Pipeline Updates, 2014 33
Symphogen A/S - Dormant Developmental Projects,2014 34
Symphogen A/S - Discontinued Pipeline Products, 2014 35
Symphogen A/S, Subsidiaries 37